Grant: CIHR Strategic Master's Award - Bioinformatics, Comput. Biology/Health Data Sci.
McMaster University
$27,000.00
Investigating germline-mediated immunoediting in glioma
FY 2025-26
Summary
Each tumour is unique due to the genetic mutations it develops, and these mutations determine how tumours grows and respond to treatment. What remains unclear is why some tumours develop certain mutations while others do not. Recent evidence suggests that the DNA we inherit from our parents may influence not only cancer risk, but also the specific mutations a tumour develops. Gliomas, the most common brain tumours in adults, offer a powerful model to explore this phenomenon. Gliomas are classified based on the mutations they have that determine both diagnosis and outcome. Survival ranges from about 70% for low-grade gliomas to less than 5% for the most aggressive forms. Understanding why some individuals develop mutations linked to poorer prognosis could transform early detection and treatment. This project will test whether inherited immune variation, particularly within the human leukocyte antigen (HLA) genes, influence cancer-associated mutations in glioma. We hypothesize that tumours that are more visible to the immune system, based on their DNA mutations and HLA genes, will be statistically depleted in our large-scale cohorts, asthe immune system would eradicate these tumours before diagnosis. This research has two key objectives: first, to identify cancer-associated mutation and HLA gene combinations for which tumours are statistically depleted. Second, to evaluate whether specific cancer-associated mutation and HLA gene combinations are associated with patient survival using multivariate regression models. By linking inherited immunity to mutation burden and outcomes in glioma, this research could help us understand the evolution of tumours and develop blood-based biomarkers for early detection and prognosis.
Department
Program
CIHR Strategic Master's Award - Bioinformatics, Comput. Biology/Health Data Sci.
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
562719
Name
Apel Erika
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Master's Award: Strategic Master's Award
Projecttitle
Investigating germline-mediated immunoediting in glioma
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
CIHR Strategic Master's Award - Bioinformatics, Comput. Biology/Health Data Sci.
Keyworddelim
Glioma; Immunoediting
Abstract
Each tumour is unique due to the genetic mutations it develops, and these mutations determine how tumours grows and respond to treatment. What remains unclear is why some tumours develop certain mutations while others do not. Recent evidence suggests that the DNA we inherit from our parents may influence not only cancer risk, but also the specific mutations a tumour develops. Gliomas, the most common brain tumours in adults, offer a powerful model to explore this phenomenon. Gliomas are classified based on the mutations they have that determine both diagnosis and outcome. Survival ranges from about 70% for low-grade gliomas to less than 5% for the most aggressive forms. Understanding why some individuals develop mutations linked to poorer prognosis could transform early detection and treatment. This project will test whether inherited immune variation, particularly within the human leukocyte antigen (HLA) genes, influence cancer-associated mutations in glioma. We hypothesize that tumours that are more visible to the immune system, based on their DNA mutations and HLA genes, will be statistically depleted in our large-scale cohorts, asthe immune system would eradicate these tumours before diagnosis. This research has two key objectives: first, to identify cancer-associated mutation and HLA gene combinations for which tumours are statistically depleted. Second, to evaluate whether specific cancer-associated mutation and HLA gene combinations are associated with patient survival using multivariate regression models. By linking inherited immunity to mutation burden and outcomes in glioma, this research could help us understand the evolution of tumours and develop blood-based biomarkers for early detection and prognosis.
Competitiondate
202601
Approvedterm2
1 yr 0 mth
Pinamesdelim
Apel, Erika
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~